China Resources Pharmaceutical Group (HKG:3320) subsidiary China Resources Boya Bio-pharmaceutical Group (SHE:300294) expects to record net profit attributable to the shareholders between 380.00 million yuan and 480.00 million yuan in 2024, higher than 237.5 million yuan logged for the preceding year, a Wednesday Hong Kong bourse filing said.
China Resources Boya Bio-pharmaceutical Group attributed the increase in expected profit to a rise in revenue from its blood products and the impact of non-recurring gains and losses on its net profit during the reporting period.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。